Plasma Interleukin-6 Predicts Clinical Decline After Completion of Dexamethasone Therapy in Severe COVID-19.

F Linzee Mabrey,Pavan K Bhatraju,Eric D Morrell,Leila R Zelnick,Neha A Sathe,Nicholas G O'Connor,Carmen Mikacenic,Thomas R Martin,W Conrad Liles,Mark M Wurfel

Critical care explorations（2022）

引用 0|浏览16

暂无评分

摘要

Clinical decline after completion of dexamethasone for severe COVID-19 is common. IL-6 concentrations obtained prior to completion of dexamethasone may have utility in identifying those at highest risk for subsequent worsening. If validated, future work might test whether plasma IL-6 could be used as a tool for a personalized approach to duration of dexamethasone treatment in severe COVID-19.

查看译文

关键词

COVID-19,dexamethasone,interleukin-6,post-dexamethasone clinical decline

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要